Autolus Therapeutics PLC
NASDAQ:AUTL

Watchlist Manager
Autolus Therapeutics PLC Logo
Autolus Therapeutics PLC
NASDAQ:AUTL
Watchlist
Price: 2.25 USD 3.21% Market Closed
Market Cap: 598.8m USD
Have any thoughts about
Autolus Therapeutics PLC?
Write Note

Autolus Therapeutics PLC
Additional Paid In Capital

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Autolus Therapeutics PLC
Additional Paid In Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Additional Paid In Capital CAGR 3Y CAGR 5Y CAGR 10Y
Autolus Therapeutics PLC
NASDAQ:AUTL
Additional Paid In Capital
$1B
CAGR 3-Years
20%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
Additional Paid In Capital
$987.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Exscientia PLC
NASDAQ:EXAI
Additional Paid In Capital
ÂŁ364.6m
CAGR 3-Years
44%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bicycle Therapeutics PLC
NASDAQ:BCYC
Additional Paid In Capital
$1.5B
CAGR 3-Years
58%
CAGR 5-Years
50%
CAGR 10-Years
N/A
Immunocore Holdings PLC
NASDAQ:IMCR
Additional Paid In Capital
ÂŁ1.1B
CAGR 3-Years
N/A
CAGR 5-Years
39%
CAGR 10-Years
N/A
Genus PLC
LSE:GNS
Additional Paid In Capital
ÂŁ179.1m
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
5%
No Stocks Found

Autolus Therapeutics PLC
Glance View

Market Cap
598.8m USD
Industry
Biotechnology

Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. The firm is focused on developing programmed T cell therapies for the treatment of cancer. The firm has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. Its lead clinical programs include AUTO1 (obecabtagene autoleucel, Obe-Cel), AUTO4, and AUTO6 / AUTO6NG. Obe-cel is a CD19 CAR T cell investigational therapy designed to overcome limitations in clinical activity and safety. Obe-cel reduces toxicity and is less prone to T cell exhaustion, which could improve persistence and the ability of programmed T cells to engage in serial killing of target cancer cells. AUTO4 is a T cell therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1. AUTO6 / AUTO6NG is a T cell therapy targeting GD2 in development for the treatment of neuroblastoma. Its other clinical programs include AUTO5, AUTO7, and AUTO8.

AUTL Intrinsic Value
5.07 USD
Undervaluation 56%
Intrinsic Value
Price

See Also

What is Autolus Therapeutics PLC's Additional Paid In Capital?
Additional Paid In Capital
1B USD

Based on the financial report for Dec 31, 2023, Autolus Therapeutics PLC's Additional Paid In Capital amounts to 1B USD.

What is Autolus Therapeutics PLC's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 3Y
20%

Over the last year, the Additional Paid In Capital growth was 1%. The average annual Additional Paid In Capital growth rates for Autolus Therapeutics PLC have been 20% over the past three years .

Back to Top